Tahir Mahmood

Tahir Mahmood is co-founder of Mindera and co-invented and developed the technology at the core of the company's platform. He is Chief Executive Officer and Co-founder at Applied Molecular Transport (NASDAQ: AMTI), a clinical stage biotech developing next generation biotherapeutics for treating immune-mediated inflammation, metabolic and other diseases. Previously, Tahir was a leader in the US West Coast Life Sciences practice at the consulting firm Booz Allen Hamilton and was Managing Director at Lake Sherwood Partners. As a consultant, he advised executives at life sciences, healthcare provider, public and private equity investment, and global health organizations. He was Visiting Investigator at The Scripps Research Institute in La Jolla, CA and was previously Principal Business Analyst at Amgen, supporting BD, M&A and strategic corporate venture fund transactions. Earlier, he was at Chienna (acquired by OctoPlus) and IsoTis (acquired by Integra Life Sciences).

Tahir has authored numerous peer-reviewed publications and is inventor on several issued and pending patents. He received a BASc in Mechanical Engineering and MSc in Biomedical Engineering from the University of Toronto, and holds a PhD in Chemical & Biomedical Engineering from a collaborative program between the University of Twente (The Netherlands) and MIT at the Harvard-MIT Division of Health Sciences and Technology and Children's Hospital Boston.